SIMBRINZA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9421265 | ALCON LABS INC | Aqueous pharmaceutical compositions containing borate-polyol complexes |
Jun, 2030
(6 years from now) | |
| US9044484 | ALCON LABS INC | Aqueous pharmaceutical compositions containing borate-polyol complexes |
Oct, 2030
(7 years from now) | |
Simbrinza is owned by Alcon Labs Inc.
Simbrinza contains Brimonidine Tartrate; Brinzolamide.
Simbrinza has a total of 2 drug patents out of which 0 drug patents have expired.
Simbrinza was authorised for market use on 19 April, 2013.
Simbrinza is available in suspension/drops;ophthalmic dosage forms.
The generics of Simbrinza are possible to be released after 30 October, 2030.
Drugs and Companies using BRIMONIDINE TARTRATE; BRINZOLAMIDE ingredient
Market Authorisation Date: 19 April, 2013
Treatment: NA
Dosage: SUSPENSION/DROPS;OPHTHALMIC
How can I launch a generic of SIMBRINZA before it's drug patent expiration?
More Information on Dosage
SIMBRINZA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic